Topics

Mallinckrodt selling CDMO business for up to $250M

09:47 EDT 12 Sep 2019 | BioPharmaDive

The deal gives needed cash to Mallinckrodt, which is under pressure for its role in the opioid epidemic, and provides another example of private equity's interest in contract manufacturing.

Original Article: Mallinckrodt selling CDMO business for up to $250M

NEXT ARTICLE

More From BioPortfolio on "Mallinckrodt selling CDMO business for up to $250M"

Quick Search